Irritable Bowel Syndrome

Several studies recently have looked at the relationship between irritable bowel syndrome and increased pain sensitivity.

Clinical trials have shown that probiotics are somewhat effective as therapy for irritable bowel syndrome, but many of the studies have been short-term and of poor quality.

Because the two conditions share similar symptoms, patients with IBS often misinterpret gastrointestinal symptoms and self-diagnose as lactose intolerant.

Patients with refractory IBS who incorporated weekly sessions of gut-directed hypnotherapy into their treatment report significant long-term improvements in quality of life.

Researchers report that skin patch testing for specific foods and additives that can cause IBS symptoms can help patients eliminate those foods from their diet and improve their IBS symptoms.

A roundup of brief summaries of news and research about irritable bowel syndrome.

A multidisciplinary research project aims to create a large IBS biobank and create uniform standards and guidelines to aid in the study of IBS and other functional GI disorders.

Study results show patients with IBS who drink four or more alcoholic drinks in one day may be more likely to experience diarrhea, nausea, stomach pain, and indigestion the next day.

The goal of IBS management should be to improve overall symptoms, including altered stool frequency and consistency, abdominal pain and discomfort, bloating, and quality of life.

Adequate daily fiber intake confers multiple health benefits, including improved management of irritable bowel syndrome.

Expert advice from the 2013 AGA-ASGE Clinical Congress of Gastroenterology and Hepatology on managing diarrhea, constipation, abdominal pain, and other symptoms associated with irritable bowel syndrome (IBS).

It is important for patients with irritable bowel syndrome (IBS) to understand more about their condition and track their diet and bowel habits to help manage their symptoms. These apps for the iPhone and iPad provide useful information for patients that can help them learn more about the symptoms and management of IBS, track their medications and daily habits, and share this information with their health care providers.

Linzess (linaclotide capsules) was approved in August 2012 by the FDA as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

The xTAG Gastrointestinal Pathogen Panel can simultaneously detect 11 common viral, bacterial, and parasitic causes of infectious gastroenteritis from a single patient sample.

Treatment with synthetic stool may produce better results and improve safety in patients with C. difficile infection that does not respond to standard therapy.

Recent study results suggest that treatment that includes patient education, cognitive behavioral therapy, and other psycho-social modalities can help reduce symptom severity and improve quality of life in patients with irritable bowel syndrome (IBS).

Ahmed Kandiel, MD, MPH, kicked off the 47th Annual Gastroenterology Update with a thorough review of the current treatment landscape for moderate to severe inflammatory bowel disease, including the potential risks for side effects for each biologic agent.

High-intensity athletes report more functional gastrointestinal disorders than athletes who engage in lower-intensity sports.

Trial of mindfulness training as an intervention for irritable bowel syndrome (IBS) demonstrates substantial therapeutic impact on bowel symptom severity.

Researchers have shown for the first time how peppermint helps to relieve Irritable Bowel Syndrome.

By eliminating need for physical exam in diagnosis of fibromyalgia, new criteria enable co-morbidity studies in patients with IBS.

A little exercise goes a long way (improving scores by as much as 51 points) towards reducing the negative effects of irritable bowel syndrome.

Researchers have uncovered an antibiotic therapy that provides continuing relief for IBS for up to 10 weeks, according to a study in NEJM.

Patients knowingly taking inert pills labeled placebo for IBS reported adequate symptom relief, comparable to the most powerful IBS medications.

When IBD patients experience loss of response to therapy, the decision to escalate the dose or switch to other drugs depends on a number of factors.

The Manchester Color Wheel helps determine which patients are most likely to respond to hypnotherapy, increasing the chances of success and reducing costs.

Molecular profiling indicates that patients with ulcerative colitis and Irritable Bowel Syndrome have notably low levels of the Bacteroides species in the gut.

Women with irritable bowel syndrome experience both increases and decreases of brain grey matter in specific cortical brain regions.

Visit this respectable, physician-authored site for a review of many IBS-related topics.